SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Risk stratification in Pulmonary Embolism and Duration of Anticoagulation

saul avatar
saul
6 diapositives · 282 Views · Jul 28, 2014

Risk stratification in Pulmonary Embolism and Duration of Anticoagulation. Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE. Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin , BNP High mortality risk > 15%

#risk stratification in pulmonary embolism and duration of anticoagulation #risk stratification in pulmonary embolism and duration of anticoagulation ppt #powerpoint #presentation
Risk stratification in Pulmonary Embolism and Duration of Anticoagulation - slide 1
01 / 6Risk stratification in Pulmonary Embolism and Duration of Anticoagulation
1 / 17

Télécharger la présentation

Risk stratification in Pulmonary Embolism and Duration of Anticoagulation
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Risk stratification in Pulmonary Embolism and Duration of Anticoagulation Respiratory CONNECT meeting Dr Julius Cairn

  2. Risk stratification in PE • Clinical parameters – shock, JVP, S3 • Imaging – CTPA, echo • Biomarkers – Troponin, BNP • High mortality risk > 15% • - shock, RV dysfunction, positive biomarkers – thrombolyse • Intermediate risk 3-15% • RV dysfunction and positive biomarkers – iv heparin • Low risk <1% mortality • Early discharge • Above knee DVT – high risk for post-thrombotic syndrome and for PE • Risk stratification should improve outcome and reduce length of stay

  3. Duration of anticoagulation • Number of studies show no benefit of 6 months over 3 months, also ACCP recommendation • Risk of recurrence returns after stopping • 0.7% per year VTE provoked by surgery • 3% per year for all patients • 7.4% per year for unprovoked event • In order to justify lifelong anticoagulation 5% or greater risk • Consider lifelong anticoagulation in idiopathic PE

  4. Improving outcomes from Community Acquired Pneumonia (CAP) Respiratory CONNECT meeting Dr Julius Cairn

  5. Late mortality from CAP • Leading cause of death from infectious disease in western countries – mortality rate 5-15% • On-going risk of mortality in months/years afterwards • >25% of deaths within 30 days are not directly related • Nearly 50% deaths overall related to comorbidties • Evidence of link between acute respiratory infections and increased risk of cardiovascular events • Incidence after CAP : 15 days – 10.7%, 90days 13%, 1 year 33% • Prior statin or ACEi treatment • Influenza/ Pneumococcal vaccination • Further define if cause of CV events and pathogenesis

  6. How differences in medical management of CAP might influence outcome • Menendes et al multicentre trial of 4,137 pts • Adherence to antibiotic guidelines • Shorter length of stay in patients without organ failure • Delivery of the first dose of antibiotic within 6 hours of presentation • Mortality better in the severe sepsis patients • Measurement of oxygenation at presentation • Doesn’t distinguish between preventable/inevitable mortality BUT medical management influence outcome • Challenge – identify bundles of practice that give best outcomes